RÉSUMÉ
We launched a survey in April 2020 to assess the number and proportion of hospital workers infected during the first wave of the COVID-19 pandemic in France, and to assess the attributable mortality. All French hospital settings (HS) were invited to declare new cases and attributable deaths by occupation category each week. Between March 1 and June 28, 2020, participating HS accounted for 69.5% of the total number of HS workers in France, and declared 31,088 infected workers; 16 died from the infection. We estimated that 3.43% (95% CI: 3.42-3.45) of French workers in HS, and 3.97% (95% CI: 3.95-3.99) of healthcare workers were infected during the first wave. Workers in regions with a cumulative rate of hospitalized COVID-19 patients equal or above the national rate, HS other than tertiary hospitals, or occupations with frequent patient contacts were particularly impacted. Targeted prevention campaigns should be elaborated.
Sujet(s)
COVID-19/épidémiologie , Hôpitaux/statistiques et données numériques , Pandémies , Personnel hospitalier/statistiques et données numériques , COVID-19/mortalité , France/épidémiologie , Hospitalisation/statistiques et données numériques , Humains , Études rétrospectives , SARS-CoV-2 , Enquêtes et questionnairesRÉSUMÉ
OBJECTIVES AND METHOD: We conducted a prospective study in 2013 to compare the whole-cell versus acellular pertussis vaccines effectiveness and duration of protection, following the occurrence of pertussis clusters. RESULTS: During seven school outbreaks, we identified 102 clinical pertussis cases, including 10 cases biologically confirmed by Bordetella pertussis specific PCR, among a cohort of 305 children in 2nd to 6th grade. The risk of pertussis when vaccinated with an acellular vaccine alone was 1.6 (RR=1.6; 95% CI=1.1-2.5) times higher than when vaccinated with a whole-cell vaccine or using a combined schedule. CONCLUSIONS: The limited duration of protection conferred by the acellular vaccine reinforces the 2013 introduction of the pertussis booster at six years old.
Sujet(s)
Épidémies de maladies , Vaccin anticoquelucheux/immunologie , Coqueluche/épidémiologie , Coqueluche/prévention et contrôle , Enfant , Enfant d'âge préscolaire , France/épidémiologie , Humains , Nourrisson , Études prospectives , Établissements scolaires , Vaccins acellulairesRÉSUMÉ
OBJECTIVE: This 2018 report of Healthcare-Associated Infections Early Warning and Response System (HAI-EWRS) notifications of carbapenemase-producing Enterobacteriaceae (CPE) or glycopeptide-resistant Enterococcus faecium (GRE), and of strains analysed by the National Reference Center for anti-microbial resistance (NRC) aimed to describe the epidemiology of emerging extensively drug-resistant bacteria (eXDR) in France and control measures implemented in hospital settings. PATIENTS AND METHODS: All HAI-EWRS notifications of eXDR received at the national level and all eXDR strains received at the NRC between January 1, 2018 and January 31, 2018 were analysed. Variables analysed were number of cases, number of strains, resistance mechanism, sample type, link with a foreign country, and control measures implemented. RESULTS: In 2018, 1704 CPE notifications and 315 GRE notifications were reported in France, with an increasing trend since 2012 (×6 for CPE, ×3 for GRE), from respectively 364 and 155 hospitals (+66% for CPE, +57% for GRE since 2012). eXDR strains were mainly isolated from rectal screening swabs. Notifications with patients receiving standard precautions were more often associated with outbreaks than notifications with patients receiving contact precautions at admission. NRC received 2674 CPE strains and 775 GRE strains in 2018 (×8.3 and ×2.8 compared with 2012). CONCLUSION: The increasing annual number of eXDR notifications and eXDR strains received by the NRC is multifactorial but reflects a worrying spread of eXDR in France. The number of infections remains low, but this article shows that existing recommendations are not fully implemented.
Sujet(s)
Enterobacteriaceae résistantes aux carbapénèmes , Infection croisée , Infections à Enterobacteriaceae , Enterococcus faecium , Préparations pharmaceutiques , Antibactériens/pharmacologie , Antibactériens/usage thérapeutique , Infection croisée/traitement médicamenteux , Infection croisée/épidémiologie , Infections à Enterobacteriaceae/traitement médicamenteux , France/épidémiologie , Humains , Prévention des infectionsRÉSUMÉ
During summer 2016, all the conditions for local mosquito-borne transmission of Zika virus (ZIKV) are met in mainland France: a competent vector, Aedes albopictus, a large number of travellers returning from ZIKV-affected areas, and an immunologically naive population. From 1 January to 15 July 2016, 625 persons with evidence of recent ZIKV infection were reported in mainland France. We describe the surveillance system in place and control measures implemented to reduce the risk of infection.
Sujet(s)
Aedes/virologie , Liquides biologiques/virologie , Immunoglobuline M/sang , Surveillance sentinelle , Voyage , Infection par le virus Zika/épidémiologie , Virus Zika/isolement et purification , Adolescent , Adulte , Sujet âgé , Animaux , Enfant , Enfant d'âge préscolaire , Notification des maladies , Épidémies de maladies/prévention et contrôle , Femelle , France/épidémiologie , Humains , Vecteurs insectes/virologie , Mâle , Adulte d'âge moyen , Surveillance de la population , RT-PCR , Jeune adulte , Virus Zika/génétique , Infection par le virus Zika/diagnostic , Infection par le virus Zika/transmissionRÉSUMÉ
INTRODUCTION: Scabies is a contagious parasitic infestation that is benign in most cases; however, delay in diagnosis and treatment can cause numerous problems for patients and people in their vicinity, as well as a risk of secondary spread. Following numerous reports suggesting increased incidence of scabies in France, we analysed various available indicators. METHODS: We analysed spontaneous and mandatory reports submitted to public health bodies as well as sales figures for scabies treatments in France over the period between 1999 and 2010. RESULTS: Reports submitted to public health structures suggest an increase in the number of cases of scabies both within the community and in healthcare establishments. An increase was seen in regional and national sales of scabies treatments. At the national level, between 2005 and 2009, sales rose from 283 to 402 bottles per 100,000 persons per year (+10% per year) for benzyl benzoate and from 216 to 495 treatments per 100,000 persons per year (+22%) for ivermectin. Based on these data, the minimum estimated annual incidence of scabies in France is 328 cases per 100,000 persons. DISCUSSION: There is some discussion surrounding the interpretation of these data, particularly the bias associated with reporting practice and with the protocols used to treat affected subjects and those in their vicinity. However, all of the information gathered indicates a real increase in the incidence of scabies in France, as a result of which we recommend increased information for the general public, clinical practitioners and public health partners in order to ensure early diagnosis and treatment.
Sujet(s)
Santé publique/statistiques et données numériques , Santé publique/tendances , Gale/épidémiologie , Antiparasitaires/usage thérapeutique , Benzoates/usage thérapeutique , Biais (épidémiologie) , Infection croisée/diagnostic , Infection croisée/traitement médicamenteux , Infection croisée/épidémiologie , Infection croisée/prévention et contrôle , Études transversales , Utilisation médicament/tendances , Prévision , France , Enquêtes de santé , Humains , Incidence , Insecticides , Ivermectine/usage thérapeutique , Récidive , Gale/diagnostic , Gale/traitement médicamenteux , Gale/prévention et contrôleRÉSUMÉ
Pertussis is not a notifiable disease in France. In addition to a paediatric hospital sentinel surveillance system, pertussis epidemiological data have, since 1996, been gathered through the voluntary notification of community clusters by general practitioners, and since 2001 by the statutory notification of nosocomial infection to the relevant local health authority. The local health authority forwards the information to the French National Institute for Surveillance (InVS). The objective of this study was to analyse pertussis data outside the routine paediatric hospital sentinel surveillance system. We gathered all the information concerning healthcare-associated infections and community clusters of pertussis (specific forms, investigation reports, emails etc.) reported to the InVS between 2000 and 2005. The InVS received and analysed 67 reports with a total of 595 cases. Almost half of the reports (n=31) came from hospitals, and healthcare workers were usually first affected. Control measures were put in place in 22 healthcare facilities and the average duration of an outbreak episode was 48 days. Outside healthcare facilities, clusters were reported also from 17 daycare facilities or schools and five workplaces. Among the 595 cases, six deaths occurred in children under seven months of age. Pertussis is still occurring in France and affects those who are not or who are no longer protected by the vaccine. Infection of infants within the household could be prevented if their parents and siblings were immunised. The number and size of pertussis clusters in hospitals could be reduced through immunisation of health staff, and timely and adequate outbreak management.
Sujet(s)
Infection croisée/épidémiologie , Épidémies de maladies/statistiques et données numériques , Surveillance de la population , Appréciation des risques/méthodes , Coqueluche/épidémiologie , Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Enfant , Enfant d'âge préscolaire , Analyse de regroupements , Infections communautaires/épidémiologie , Femelle , France/épidémiologie , Humains , Incidence , Nourrisson , Nouveau-né , Mâle , Adulte d'âge moyen , Facteurs de risqueSujet(s)
Clostridioides difficile/classification , Clostridioides difficile/isolement et purification , Entérocolite pseudomembraneuse/épidémiologie , Entérocolite pseudomembraneuse/virologie , Ribotypage , Sujet âgé de 80 ans ou plus , Clostridioides difficile/génétique , Infection croisée/diagnostic , Infection croisée/épidémiologie , Infection croisée/virologie , Entérocolite pseudomembraneuse/diagnostic , France/épidémiologie , Humains , Réaction de polymérisation en chaîne/méthodes , Ribotypage/méthodesSujet(s)
Toxines bactériennes/classification , Clostridioides difficile/classification , Clostridioides difficile/génétique , Entérocolite pseudomembraneuse/épidémiologie , Entérocolite pseudomembraneuse/microbiologie , Réaction de polymérisation en chaîne , Ribotypage , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Clostridioides difficile/métabolisme , Analyse de regroupements , Infection croisée/épidémiologie , Infection croisée/microbiologie , Infection croisée/mortalité , Entérocolite pseudomembraneuse/mortalité , Femelle , France/épidémiologie , Humains , Incidence , Prévention des infections , Mâle , Adulte d'âge moyen , Ribotypage/méthodesRÉSUMÉ
OBJECTIVES: The authors had aimed to evaluate resources and organization necessary for applying guidelines issued 5 years earlier in various institutions: standard precautions, septic isolation, prevention against spread of multidrug-resistant bacteria. MATERIAL AND METHODS: Volunteer institutions were surveyed for hygiene product consumption, architectural requirements, inventory of protocols, description septic patients'management, and available personnel. RESULTS: One hundred and twenty-four institutions (40,784 beds) were included in the study. Eleven percent had no hygiene physician or nurse; the rates of personnel specialized in hygiene practice were 0.4 physicians per 800 beds and 0.8 registered nurses per 400 beds. Eighty-eight percent of the studied institutions had a protocol for standard precautionary measures, 77% had a septic isolation protocol. A multidrug-resistant bacteria identification sheet was attached to examination reports in 87% of cases. Multidrug-resistant bacteria screening was practiced by 18.1% of the institutions. Hygiene product consumption for 1000 days of hospitalization was 7861 disposable gloves, 2.3 1 of hydroalcoholic solution, and 63 disposable gowns. 28.9% of the wards lacked water hand washing points, 32.2% had no sinks, and 48.5% had no local equipment maintenance. In addition, 40.7% of the beds were in single rooms, 4.8% of the institutions had no single rooms. Differences were observed depending on specialties and institutions. CONCLUSION: Analysis of consumption shows insufficient application of standard precautions, notably for hydroalcoholic solutions. The number of single rooms is acceptable, architectural requirements were not adequate in too many wards. These results can explain some problems encountered in applying the guidelines.
Sujet(s)
Multirésistance aux médicaments , Adhésion aux directives , Établissements de santé/économie , Administration d'établissement de santé , Prévention des infections/organisation et administration , Collecte de données , France , Établissements de santé/statistiques et données numériques , Ressources en santé/statistiques et données numériques , Humains , Hygiène , Prévention des infections/économie , Prévention des infections/statistiques et données numériques , Isolement du patientRÉSUMÉ
OBJECTIVE: To review the literature on the TT virus. METHODS: The literature review was based on articles identified through MEDLINE between Jan. 1, 1997, and August 15, 1999. RESULTS: In 1997, a new DNA virus, designated TTV, was isolated and seemed to be associated with non A-G post-transfusion hepatitis. The virus was identified using a polymerase chain reaction (PCR) because serology was not routinely available. At least 16 genotypes were identified. Depending on the PCR technique used, the prevalence of infection ranged from 17% to 71% in a group of sera tested. The prevalence rate ranged from 1.2% to 62% among blood donors, from 0.5% to 83% among hemophiliacs and from 1% to 71% in cases of chronic hepatitis. The current hypothesis is that routes of infection were parenteral and orofecal. The pathogenesis of this virus, if it really exists, is not yet clearly established. It has been postulated that some interaction may exist between the TT virus and the hepatitis C virus. The use of interferon seems to decrease the TT viremia, according to results obtained outside the context of clinical trials. CONCLUSION: The pathogenesis of the TT virus needs to be rapidly established for transmission prevention and therapeutic intervention.